Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CellPoint B.V.
The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.
- Contract Research Organization-CRO
- Gene Therapy, Cell Therapy